第59届欧洲糖尿病研究学会(European Association for the Study of Diabetes, EASD)年会于2023年10月2日至6日在德国汉堡召开。在过去的数十年间，糖尿病临床诊治取得巨大进展，新型降糖药物尤其是基于胰升糖素样肽1受体及靶向双重/多重受体的疗法备受关注。这些药物在降糖、减重、改善代谢及至更多额外获益方面，均具有非常值得关注的前景。本文简要介绍本届EASD大会上的一些热点话题。 The 59th European Association for the Study of Diabetes(EASD) annual meeting was held in Hamburg, Germany from October 2nd to 6th, 2023. In the past decades, there have been significant advancements in the clinical management of diabetes. Novel anti-hyperglycemic medications, particularly those targeting the glucagon-like peptide-1 receptor and dual/multiple receptors, have garnered attention. These medications show great promise in glycemic control, weight reduction, metabolic improvements, and additional benefits. This article provided an overview of some of the key topics discussed at this EASD conference.
Proceedings of the 2023 annual meeting of European Association for the Study of Diabetes: Advances in diabetes mellitus and other metabolic diseases
The 59th European Association for the Study of Diabetes(EASD) annual meeting was held in Hamburg, Germany from October 2nd to 6th, 2023. In the past decades, there have been significant advancements in the clinical management of diabetes. Novel anti-hyperglycemic medications, particularly those targeting the glucagon-like peptide-1 receptor and dual/multiple receptors, have garnered attention. These medications show great promise in glycemic control, weight reduction, metabolic improvements, and additional benefits. This article provided an overview of some of the key topics discussed at this EASD conference.
Diabetes mellitusComplications/ComorbiditiesMetabolic DiseasesObesityEuropean Association for the Study of Diabetes
万方数据
